Pain management solution offered by Promex and Realeve honored by MedTech Breakthrough Awards
In the realm of medical technology, one device is making waves in the treatment of central nervous system (CNS) disorders – the Pulsante system, developed by Realeve. This externally powered implantable neuromodulation device system is the first of its kind, offering patients a drug-free, safe, and effective treatment option for conditions such as chronic migraine and neuropathic pain.
Realeve, a medical device company focused on developing treatments for CNS disorders via micro-neurostimulation, has been at the forefront of this innovation. The company's founder and CEO, Dr. Peter Bonutti, boasts over 30 years of experience and has more than 500 patents to his name.
The Pulsante system, when activated by a handheld device, delivers micro-neurostimulation to the sphenopalatine ganglion (SPG). This targeted stimulation has shown remarkable results in studies of chronic cluster headaches, with 75% of participants reporting a significant reduction in headache frequency and intensity over a four-week period.
The technology behind Pulsante is expected to treat other conditions linked to nerve dysfunction, such as sleep disorders and anxiety. Future iterations may even incorporate AI-based pain tracking and predictive analytics, further enhancing its capabilities.
Pulsante offers patients greater independence and improves quality of life by improving healthcare delivery. It reduces reliance on medications and provides a more holistic treatment approach. The device has FDA Breakthrough Device designation and has been clinically proven in over 700 patients.
In 2025, Realeve's Pulsante received the MedTech Breakthrough Award for Best New Pain Management Technology Solution, further cementing its position as a game-changer in the field.
While recent advancements in micro-neurostimulation technology for CNS disorders are being made, Pulsante by Realeve seems to be less covered in public reports, suggesting it might focus on different or earlier-stage aspects of this technology. For detailed and up-to-date information on Pulsante by Realeve, direct company sources, specialized neuromodulation publications, or recent scientific conferences would likely provide the latest data.
Meanwhile, other companies like Nalu Medical are making strides in neurostimulation technology. Their next-generation Therapy Disc, a wireless external power source for a miniaturized implantable pulse generator (micro-IPG), is an example of how wearable neurostimulation devices are becoming smaller, lighter, and more comfortable, enhancing patient experience with peripheral nerve stimulation for chronic pain.
As the world of medical technology continues to evolve, it's clear that the Pulsante system by Realeve is redefining chronic pain management across various neurological conditions.
- Realeve's Pulsante system, recognized for its advancements in digital health, focuses on the treatment of neurological disorders, particularly central nervous system conditions such as chronic migraine and neuropathic pain.
- Pulsante's micro-neurostimulation technology, when activated by a handheld device, targets the sphenopalatine ganglion (SPG) and has shown significant results in studies on chronic cluster headaches.
- In addition to treating headaches, the Pulsante system is expected to address other medical-conditions linked to nerve dysfunction, including sleep disorders and anxiety, and may incorporate AI-based pain tracking and predictive analytics in future iterations.
- Beyond Pulsante, other companies like Nalu Medical are also innovating in neurostimulation technology, developing wearable devices like the Therapy Disc for peripheral nerve stimulation, aiming to improve patient experience with chronic pain and contribute to the evolution of health-and-wellness solutions.
